Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 10/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089140 | 0.89 | PPARG (0.46) | PPARGPPARAMAPT | |
| SCHEMBL4097225 | 0.85 | KDM4E (0.47) | KDM4EHTTSMN1; SMN2PPARGPPARA | |
| SCHEMBL4918614 | 0.77 | PPARG (0.47) | KDM4EPPARGPPARAKDR | |
| SCHEMBL4228507 | 0.76 | SCN9A (0.48) | — | |
| SCHEMBL3009731 | 0.76 | PTGES (0.52) | SMN1; SMN2PPARGPPARAMAPTTP53 | |
| SCHEMBL4096031 | 0.76 | PTGES (0.43) | KDM4EHTTMAPTTP53 | |
| SCHEMBL4101335 | 0.75 | PTGES (0.43) | KDM4EPPARAMAPTTP53 | |
| SCHEMBL4924224 | 0.75 | PLA2G10 (0.49) | PPARG | |
| SCHEMBL4920933 | 0.75 | PTGES (0.48) | SMN1; SMN2MAPTTP53 | |
| SCHEMBL333779 | 0.74 | PPARG (0.47) | KDM4ESMN1; SMN2PPARGPPARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | KDM4E 1407/4885HTT 3312/4885SMN1; SMN2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.